Ombitasvir

Ombitasvir

Clinical data
Trade names	Viekira Pak, Viekira XR (with ombitasvir, paritaprevir, ritonavir and dasabuvir), Technivie (with ombitasvir, paritaprevir, and ritonavir)
Other names	ABT-267
License data	EU EMA: by INN
Routes of administration	By mouth (tablets)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	Not determined
Protein binding	~99.9%
Metabolism	Amide hydrolysis followed by oxidation
Onset of action	~4 to 5 hours
Elimination half-life	21 to 25 hours
Excretion	Mostly with feces (90.2%)
Identifiers
IUPAC name Dimethyl N,N′-{[(2S,5S)-1-(4-tert-butylphenyl)pyrrolidene-2,5-diyl]-bis-{[(4,1-phenyleneazanediyl)carbonyl] [(2S)-pyrrolidine-2,1-diyl]}[(2S)-3-methyl-1-oxobutane-1,2-diyl])}biscarbamate
CAS Number	1258226-87-7
PubChem CID	54767916
ChemSpider	31136214
UNII	2302768XJ8
KEGG	D10576 Y
ChEBI	CHEBI:85183 Y
CompTox Dashboard (EPA)	DTXSID201027920
Chemical and physical data
Formula	C50H67N7O8
Molar mass	894.127 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)Nc2ccc(cc2)[C@@H]3CC[C@H](N3c4ccc(cc4)C(C)(C)C)c5ccc(cc5)NC(=O)[C@@H]6CCCN6C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
InChI InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1 Key:PIDFDZJZLOTZTM-KHVQSSSXSA-N

Ombitasvir is an antiviral drug for the treatment of hepatitis C virus (HCV) infection by AbbVie. In the United States, it is approved by the Food and Drug Administration for use in combination with paritaprevir, ritonavir and dasabuvir in the product Viekira Pak for the treatment of HCV genotype 1, and with paritaprevir and ritonavir in the product Technivie for the treatment of HCV genotype 4.

Ombitasvir is an NS5A inhibitor that acts by inhibiting the HCV protein NS5A.

See also

• Discovery and development of NS5A inhibitors

Further reading

• Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, et al. (November 2018). "Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials". Open Forum Infectious Diseases. 5 (11): ofy248. doi:10.1007/s15010-018-1157-x. OCLC 1105037362. PMC 6222025. PMID 30430131.
• Petta S, Marzioni M, Russo P, Aghemo A, Alberti A, Ascione A, et al. (June 2017). "Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study". The Lancet. Gastroenterology & Hepatology. 2 (6): 427–434. doi:10.1016/S2468-1253(17)30048-1. hdl:11390/1119739. PMID 28497758.